David Gallardo was graduated in medicine in 1990 at the University of Barcelona and trained in Hematology in the “Ciutat Sanitària de Bellvitge” from 1991 to 1994. In 1996 he stayed at The Anthony Nolan Research Institute (London, UK) developing new techniques to explore polymorphic genetic Systems including HLA in hematopoietic stem cell transplant from related and unrelated donors. Back in Barcelona, he was awarded with the Spanish Josep Carreras grant and started the Alloreactivity project at the Catalan Institute of Oncology (ICO) with direct supervision of Professor Donall E. Thomas. He obtained his Ph.D. degree in 1998.

From 2000 to 2007 he was a staff member of the Hematology Department of the Catalan Institute of Oncology (L’Hospitalet, Barcelona) being involved in medical management of patients with acute leukemia and/or receiving hematopoietic transplant, leading translational research activity in these fields.

In 2007 he moved to Girona to lead the Department of Hematology of the Catalan Institute of Oncology (ICO) at the Josep Trueta Hospital. In 2009 he started the Hematopoietic stem cell transplant activity in Girona, where he is still the Director of the Stem Cell Transplantation Program.

From 2016 to 2020 he was Medical Director of the Catalan Oncology Institute in Girona.

He has been Associate Professor of Medicine at the University of Girona (UdG) from 2010 to 2021, and Full professor since 2021.

He joined the Josep Carreras Institute in 2021.

Dr. Gallardo's research focuses on the study of genetic markers involved in the alloreactivity after allogeneic stem cell transplantation as well as on acute myeloid leukemia genetic prognostic factors.

He is author or co-author of original articles published in top scientific journals such as Nature Genetics, Blood, Leukemia, British Journal of Haematology, Haematologica or Bone Marrow Transplantation.